Johnson & Johnson (JNJ): A Bull Case Theory

We came across a bullish thesis on Johnson & Johnson on Max Dividends’s Substack. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson's share was trading at $205.34 as of December 1st. JNJ’s trailing and forward P/E were 19.99 and 17.99 respectively according to Yahoo Finance.

Johnson & Johnson (J&J) is a global healthcare leader with three major divisions: pharmaceuticals, medical devices, and consumer health products. Pharmaceuticals remain its largest growth engine, treating cancer and immune disorders, while medical devices provide long-term hospital partnerships through surgical tools and implants. Its consumer health brands, including Tylenol, Band-Aid, and Listerine, add stability and everyday relevance. This diversified structure ensures recurring demand, global reach, and resilient cash flows regardless of economic cycles.

J&J’s consistency and shareholder focus make it a Dividend King, having raised dividends for 62 consecutive years with mid-single-digit growth, supported by a conservative payout ratio of around 55–60%. Financially, the company is robust — revenues climbed from $70 billion in 2015 to nearly $89 billion in 2024, operating income expanded to over $61 billion, and debt remains modest with a 0.6 debt-to-equity ratio. These fundamentals give J&J one of the strongest balance sheets in corporate America.

The MaxDividends framework scores J&J above 90, affirming its stability across five pillars: sales growth, profit growth, net income resilience, payout safety, and low leverage. With a MaxRatio of 4.67, J&J sits in the Balanced Eagle category, combining moderate dividend yield (2.8%) and steady growth (~6%). Valuation metrics show the stock is slightly undervalued versus peers and its 10-year average, offering a marginally higher yield than usual. While analysts see limited short-term upside near $188/share, J&J remains a high-quality compounder ideal for dividend-focused portfolios, balancing reliable income with sustainable long-term growth.

Previously we covered a bullish thesis on Johnson & Johnson (JNJ) by The Antifragile Investor in January 2025, which highlighted the company’s transformation toward Innovative Medicine and MedTech after the Consumer Health spin-off. The company’s stock price has appreciated approximately by 40.42% since our coverage. The thesis still stands as JNJ maintains strong fundamentals. Max Dividends shares a similar view but emphasizes dividend strength and valuation.

Johnson & Johnson is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 95 hedge fund portfolios held JNJ at the end of the second quarter which was 91 in the previous quarter. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.